By Daniella Parra
Callio Therapeutics presented preclinical data at AACR that supports the first dual-payload antibody drug conjugate in Phase 1 for HER2-expressing cancers.
While approved ADC drugs like Enhertu work initially, treatment resistance builds over time because of its single-payload approach, Callio said. The technology is designed to prevent that resistance and deliver more durable responses.
“CLIO-8221 is the first program from Callio’s dual-payload ADC pipeline to enter the clinic, just one year after our launch, underscoring our commitment to advancing innovative dual-payload ADCs for cancer,” said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer of Callio Therapeutics.
Never Miss our Weekly Highlights HERE
